The Pharmacy Compounding Advisory Committee (PCAC) is the FDA committee that votes on which substances belong on the 503A bulks list and where they sit (Category 1, 2, or 3). It is the formal venue where research peptide policy gets made.
Recent PCAC meetings covered on this site: GHK-Cu, BPC-157, sermorelin, and several other research peptides whose status has been in flux. The committee has also been the public-comment arena for the 19 injectable peptides covered in the FDA's 2023 effective ban — the same list ProPublica reported RFK Jr. is preparing to reverse. The next meeting is the July 23-24, 2026 peptide session (docket FDA-2025-N-6895); the FDA confirmed in early May that Day 2 will evaluate Emideltide (delta sleep-inducing peptide, DSIP), Semax, and Epitalon for inclusion on the 503A bulks list, with written comments due July 9 and oral-presentation requests by June 30.
Stories here cover meeting minutes, vote outcomes, public comments, and the petitions that drive new substances onto the agenda. See #fda-pcac for the alternate tag and #503a for the bulks list itself.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
Bloomberg Businessweek published a long-form feature June 17 mapping the peptide gold rush as black-market wellness drugs move toward legitimacy ahead of the July 23-24 PCAC meeting. The piece centers on Janoshik Analytical, a Prague-based purity-testing operation that grew its peptide test volume by more than 1,200% from 2023 to 2025 and reports almost nine figures in annual revenue. Investor estimates put the current US black market at $1-3 billion. Bloomberg reports peptides are now being pitched to menopausal suburban moms and offered at med spas as a casual add-on to Botox, with FDA-regulated peptide pricing strategy now an active question for entrepreneurs, investors, and incumbents alike.
A JAMA Viewpoint published June 15 by researchers from the University of Queensland, the University of Toronto, and the University of California, San Francisco flagged a fast-growing but poorly characterized trend: social-media-promoted injectable peptides for muscle growth, recovery, anti-aging, and cognition. The piece notes 130,000-plus Instagram posts and over 230 million TikTok views as of May 2026, plus a 6x rise in worldwide Google searches for 'peptides' between 2024 (1.3M/month) and 2026 (~8M/month). Substances cited include BPC-157, TB-500, and CJC-1295. The authors call for accelerated safety research and clearer regulation; the piece lands six weeks before the July 23-24 PCAC meeting that will weigh seven of those same substances for 503A compounding status.
The Hill ran a Washington-policy framing of the July 23-24 PCAC peptide-compounding meeting, casting the agenda as the regulatory follow-through on HHS Secretary Robert F. Kennedy Jr.'s repeated pledges to ease access to wound-healing, weight-loss, and longevity peptides favored by the Make America Healthy Again movement. The committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. Written comment closes July 9; oral-presentation requests close June 30, eighteen days from today.
AMC Defense Law's June 2026 'Justice Watch' note read the peptide enforcement signal: compounding pharmacies receiving warning letters and losing licenses, telehealth companies facing criminal indictments, and bulk-substance vendors under federal scrutiny. The FDA has issued more than 50 warning letters to peptide vendors and compounders in 2024-2025, and the agency has signaled an aggressive 503A/503B stance heading into the July 23-24 PCAC meeting that will rule on whether seven peptides return to legal compounding status.
A June 9 Pharmacy Times analysis broke down what HHS Secretary Robert F. Kennedy Jr.'s February 27 announcement of Category 2 to Category 1 reclassification actually means for licensed compounding pharmacies. The piece emphasized that reclassification does not mean FDA approval and that BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C still need PCAC review on July 23-24 before formal addition to the 503A bulks list. Google search volume for 'peptides' rose from 1.3 million per month in 2024 to roughly 8 million per month in 2026.
Nature published a long-read on June 8 reviewing the consumer peptide boom against the actual evidence base. Worldwide Google searches for 'peptides' rose from about 1.3 million per month in 2024 to around 8 million in 2026, fueled by social media. Most popularly promoted compounds (BPC-157, TB-500, GHK-Cu, CJC-1295) rest on animal data, with one human study described as showing 'significant methodological problems and no control group.' The piece lands two months before the July 23-24 PCAC meeting that will rule on whether seven of these peptides can return to legal 503A compounding.
A STAT and Undark investigation, supported by the Pulitzer Center and widely republished around June 1-2, examined the thin evidence behind BPC-157, the wound-healing peptide on the FDA's July 23-24 PCAC docket. Nearly all of the roughly 200 BPC-157 studies indexed on PubMed list Croatian researcher Predrag Sikiric or colleague Sven Seiwerth as an author, a concentration a Polish review team flagged as a confirmation-bias risk, and Sikiric's undisclosed conflicts include patents dating to 1989 and a CEO role at Diagen, which sells a patented version. Only three human studies have been published; STAT ran a June 1 follow-up carrying Sikiric's response to skeptics.
With EASL and ASCO dominating the clinical-data cycle, the FDA peptide-compounding regulatory track continues moving toward the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. Twelve peptides came off the FDA Category 2 'significant safety risk' bulks list effective April 23, 2026; seven of those (BPC-157, TB-500, KPV, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) advance to the July PCAC for affirmative 503A bulks-list inclusion. A second PCAC before end of February 2027 reviews five more (GHK-Cu injectable, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF). Removal from Category 2 does not yet permit compounding — that requires the affirmative PCAC recommendation plus FDA final determination (6-12 month timeline). The parallel 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide closes public comments June 29. The compounded-semaglutide shipment volume is down 90% year-over-year per the BSR Intelligence briefing as the regulatory vise tightens on the gray-market segment.
Umbrella Labs announced Monday May 25 a documentation and traceability update for its Epitalon peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's standardization initiative focused on identity-field consistency, record continuity, and reproducibility — the same template Umbrella applied to Dihexa on May 19. Epitalon (Glu-Asp-Gly-Lys) is a four-amino-acid peptide originally derived from the bovine pineal gland by Vladimir Khavinson and studied as a senescent-cell modulator and telomerase activator. The peptide is on the FDA's PCAC review docket for July 23-24, 2026 — Day 2 alongside Emideltide/DSIP and Semax — for potential 503A bulks-list inclusion. Reference-material standardization across the research-peptide supply chain is the soft regulatory signal that compounding pharmacies and supply networks are preparing for the PCAC review window.
Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).
Umbrella Labs announced Tuesday May 19 a documentation and traceability update for its dihexa peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's ongoing standardization initiative focused on identity-field consistency, record continuity, and reproducibility support for research laboratories. The timing aligns with the FDA-confirmed February 2027 PCAC meeting that will review dihexa acetate for potential 503A bulks-list inclusion alongside GHK-Cu, Melanotan II, LL-37, and PEG-MGF. Dihexa is a small angiotensin IV-derived peptide originally studied at Washington State University for hepatocyte growth factor activation and neuroprotection. Reference-material traceability standards are a soft signal of the regulatory cycle compounding pharmacies and supply chains are preparing for ahead of the PCAC review.
The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.